drugset / Trial / NCT03718884
A Study of Mirikizumab in Participants With Plaque Psoriasis
Non-randomizedSequentialOpen-labelBasic science
Summary
This study is known as a "drug interaction study." The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the bloodstream after taking a "cocktail" (combination) of them before and after multiple doses of mirikizumab. The study will last about 23 weeks for each participant. Screening must be completed within 4 weeks prior to study start.
Timeline
- Start
- 2018-10-23
- Primary completion
- 2019-10-28
- Completion
- 2019-10-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Caffeine | Small molecule | 100 mg | Oral |
| Subject | Dextromethorphan | Unknown | 30 mg | Oral |
| Subject | Midazolam | Small molecule | 1 mg | Oral |
| Subject | Mirikizumab | Monoclonal antibody | 250 mg | Subcutaneous |
| Subject | Omeprazole | Other / unclassified | 20 mg | Oral |
| Subject | Vitamin K | Unknown | 10 mg | Oral |
| Subject | Warfarin | Small molecule | 10 mg | Oral |